Toronto, Ontario – October 31, 2025 — PharmaDrug Inc. (CSE: PHRX; OTC Pink: LMLLF), a specialty pharmaceutical company focused on the research, development, and commercialization of natural medicines and controlled substances, has announced a comprehensive debt restructuring plan involving the issuance of $445,686 in secured convertible debentures. This strategic move, approved by existing debt holders, replaces previously matured instruments and ensures operational continuity across PharmaDrug’s innovative programs in psychedelics and natural-medicine therapeutics. The restructured debentures will mature on October 13, 2026, offering conversion flexibility and strengthening the company’s financial and regulatory footing as it continues its biopharmaceutical development initiatives.
Science Significance
PharmaDrug’s scientific vision lies in the modernization of natural medicines and repurposing of established compounds through biotechnology and pharmaceutical innovation. The company, through its majority-owned subsidiary Sairiyo Therapeutics, is advancing a patented reformulation of cepharanthine, a natural alkaloid compound with demonstrated anti-inflammatory, antiviral, and anticancer properties. This reformulated drug candidate has shown promising third-party validated efficacy in models of infectious disease and rare cancers. By applying pharmaceutical-grade reformulation and controlled-substance R&D, PharmaDrug is bridging traditional natural-medicine research with rigorous GxP scientific standards, expanding its footprint in next-generation therapeutic discovery.
Regulatory Significance
The debt restructuring supports ongoing regulatory compliance by ensuring sufficient capital to sustain PharmaDrug’s GxP-aligned operations and clinical advancement programs. Its subsidiary, Sairiyo Therapeutics, is conducting research designed for clinical trial submission under U.S. FDA and European regulatory frameworks. The restructuring allows uninterrupted progress toward regulatory filings, IND-enabling studies, and quality audits necessary for compliance with Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP). By maintaining liquidity and eliminating past-due liabilities, PharmaDrug strengthens its regulatory readiness, ensuring that capital constraints do not disrupt clinical governance, trial continuity, or data integrity.
Business Significance
Advertisement
This strategic debt restructuring positions PharmaDrug for greater financial stability and improved capital efficiency. The issuance of secured convertible debentures provides the flexibility to convert debt into equity, optimizing the balance sheet and allowing for reinvestment in R&D. The restructuring eliminates overdue liabilities without accruing additional interest—unless delayed at maturity—demonstrating prudent financial stewardship. It also signals strong confidence from existing investors, reinforcing the company’s long-term growth trajectory and enabling uninterrupted progress in its drug pipeline. The decision aligns with PharmaDrug’s corporate objective of maintaining compliance-driven innovation while safeguarding investor trust and shareholder value.
Patients’ Significance
For patients, this restructuring ensures that drug development programs targeting rare diseases, infections, and non-psychiatric conditions remain on track. The lead asset, Sairiyo’s cepharanthine reformulation, offers potential for safer, more accessible therapies that repurpose proven natural compounds for unmet clinical needs. Moreover, ongoing R&D in psychedelic-derived medicines for non-neuropsychiatric disorders could yield novel treatment paradigms with improved safety and regulatory control. By securing financial stability, PharmaDrug reaffirms its commitment to advancing patient-centric therapies that combine scientific validation with consistent manufacturing and ethical clinical practices.
Policy Significance
PharmaDrug’s initiatives align with emerging healthcare policy trends supporting the integration of natural medicines and controlled-substance research under robust regulatory oversight. The restructuring not only enhances compliance with financial disclosure and corporate governance obligations under Canadian Securities Exchange (CSE) rules but also enables the company to adhere to international pharmacovigilance and reporting standards. In the broader context, PharmaDrug contributes to policy objectives encouraging safe, evidence-based natural therapeutic development, demonstrating how financial resilience underpins regulatory continuity and scientific accountability within the global biopharma landscape.
Through this restructuring, PharmaDrug Inc. has effectively aligned its financial framework with its scientific and regulatory priorities, securing the resources necessary to advance cutting-edge programs in natural and controlled-substance medicines. The company’s proactive approach exemplifies how strategic financial management can sustain long-term GxP compliance and innovation, ensuring continued delivery of safe, high-quality therapeutics. As PharmaDrug prepares for its next phase of development, its focus on research integrity, fiscal responsibility, and regulatory alignment reinforces its standing as a forward-looking player in the global biopharmaceutical sector.
